Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

MHRA Updates IDAP Guidance as Only Pilot Device Authorisation Closes

The MHRA updated its IDAP guidance on 19 November 2026 to record that the pilot’s only Unmet Clinical Need Authorisation has closed.

Published 19 Nov 2026· 8 minute read
Office building at 10 South Colonnade beside Canary Wharf DLR station in London, an address used by the MHRA
Photo: The wub / Wikimedia Commons, CC BY-SA 4.0 (cropped). Source · Licence

On 19 November 2026 the MHRA updated its guidance on the Innovative Devices Access Pathway (IDAP) to record that the only Unmet Clinical Need Authorisation issued during the pilot, held by HistoSonics Inc for its EDISON system, is now closed because the device is supplied under a valid CE mark. The pilot itself remains closed to new applications.

What the MHRA changed on 19 November 2026

The MHRA’s IDAP guidance page lists the 19 November 2026 change as an update to the Unmet Clinical Need Authorisation (UCNA) attachment, to reflect that one authorisation, reference IDAP/DEU/009/2024/0001, has closed. The UCNA page carries the same update date and gives the reason: the device moved to supply under a valid CE mark, so the authorisation was closed.

The page states that only one UCNA was issued during the pilot. It was issued to HistoSonics Inc for the EDISON System and Accessories on 30 April 2025. The guidance history records an extension in April 2026 and gives the expiry as 30 October 2026. The status is now shown as closed.

This is a maintenance update to a pilot record, not a new scheme. The MHRA has not opened a new application window, and the guidance does not set eligibility criteria or deadlines for new IDAP applicants, because the pilot application guidance is marked as closed.

Key details: what IDAP and a UCNA are

The MHRA describes IDAP as a pilot that aims to speed up development of innovative medical devices that address an unmet clinical need in the NHS, offering developers an integrated regulatory and access pathway. Eight applicants were selected and receive support from IDAP partners at key stages of product development.

A UCNA lets a manufacturer place a non-UKCA or non-CE marked medical device on the Great Britain market where that is in the interest of protecting public health. According to the MHRA’s page, it:

  • is based on the MHRA’s Exceptional Use Authorisation and is granted for a set period, exempting the manufacturer from certain regulatory requirements;
  • is reviewed individually, issued directly to the manufacturer and covers supply in Great Britain only;
  • is not a general route to the UK market and applies only to products selected for the IDAP pilot;
  • carries conditions, including access limited to a specified patient population and a duty to report safety and performance data to the MHRA, and the manufacturer must show ongoing progress toward full conformity.

The legal basis is regulations 12(5), 26(3) and 39(2) of the Medical Device Regulations 2002, which allow the Secretary of State to authorise such devices where the MHRA is satisfied that doing so serves the interests of health protection. To qualify, the MHRA must find that the technology addresses a critical unmet clinical need, that there is sufficient data showing the product is safe and potentially effective, and that the manufacturer is working toward regulatory approval or certification.

Item Detail (MHRA guidance)
Manufacturer HistoSonics Inc
Device EDISON System and Accessories
MHRA reference IDAP/DEU/009/2024/0001
Issued 30 April 2025
Expiry 30 October 2026 (extension recorded April 2026)
Status Closed, device now supplied under a valid CE mark

Background: the pilot, its partners and its dates

The Department of Health and Social Care and the MHRA announced IDAP on 19 September 2023 with £10 million of government funding. The launch announcement names DHSC, Health Technology Wales, the MHRA, NHS England, the National Institute for Health and Care Excellence (NICE), the Office for Life Sciences and the Scottish Health Technologies Group as partners. The support on offer included a product roadmap, joint scientific advice, help with health technology assessments and, where safety standards were met, exceptional use authorisation from the MHRA.

At launch, eligible devices lacked a CE mark, UK CA mark or other regulatory approval, addressed a significant unmet clinical need, and came with proof of concept from a near-final prototype and clinical input from at least one UK health organisation or medical charity. Commercial and non-commercial innovators in the UK and abroad could apply.

The update history on the IDAP guidance page sets out what followed:

  • applications closed on 1 November 2023;
  • eight applicants were selected, with the pilot pages updated in February 2024;
  • Lenus Health exited the pilot in March 2025;
  • the pilot phase and the patient and public engagement pages were closed in April 2025;
  • the HistoSonics extension was recorded in April 2026.

The planned successor: an Early Access service

On 31 July 2025 the MHRA published a Statement of Policy Intent on early access to innovative medical devices. It says the service would turn the UCNA tool used in the IDAP pilot into a business-as-usual Early Access service available to innovators outside IDAP, with an initial focus on innovative diagnostic devices that support the NHS’s most urgent needs. The statement describes “controlled and time-limited access” to devices that address unmet clinical needs, and says it sets out only the MHRA’s initial thinking. It gives no launch date and says the service will be developed over the coming months.

For applicants, the statement says devices could receive time-limited authorisation with conditions for safety monitoring and data collection, and must show continued progress toward full regulatory approval. Applicants could get advice on eligibility for a fee, and the MHRA says it will communicate milestones, documentation expectations and benefit-risk criteria early.

Reaction and analysis

Law firm Pinsent Masons, in an Out-Law analysis of 4 August 2025, quoted partner Catherine Drew saying the scheme could make the UK a more attractive market for new products, but that its success depends on the MHRA and NICE being aligned, otherwise patients may not benefit widely. Partner Gareth Morgan pointed to the joined-up MHRA and NICE approach of the ILAP medicines pathway and warned of a gap where a device holds an IDAP UCNA but NICE does not recommend it for NHS use. The firm’s takeaways for developers were to seek early regulatory advice, plan for NICE or other NHS reimbursement from the start, and prepare for milestones, documentation, safety monitoring and data collection.

The HistoSonics case shows the end state a UCNA is meant to bridge. Medical Economics reported on 13 July 2026 that HistoSonics received CE mark approval for the EDISON system, allowing commercialisation across Europe and other markets that recognise the mark. The device is intended for non-invasive, image-guided destruction of liver tumours, including unresectable tumours, using focused ultrasound. The report says the approval relied in part on the #HOPE4LIVER pivotal trial, which enrolled patients in the US and Europe, including sites in Germany, Italy, Spain and the UK, and reported 90% local tumour control at 12 months with a low complication rate; long-term follow-up is still being collected. The device received FDA De Novo clearance in the US in October 2023. The report says regulators have not assessed outcomes such as overall survival, and that only physicians who have completed HistoSonics training may use it.

What it means for developers, universities, NHS research teams and research offices

  • Device developers: there is no open IDAP application route to plan around. Authorisation under a UCNA was tied to the pilot and, in the one case issued, ended once a valid CE mark was in place. Developers should treat the Early Access service as the route to watch and track the MHRA’s innovation pages for its terms.
  • University spin-outs and technology transfer offices: a UCNA exempts a manufacturer from certain requirements for a set period, but it is not conformity. Licensing and investment plans need a path to full certification, since the MHRA requires evidence of progress toward it. See the guides on CE marking and what counts as a medical device.
  • NHS research teams: a UCNA limits access to a specified patient population and requires safety and performance reporting to the MHRA. Teams running studies that feed that evidence base should check how their device trial design and data collection map to those reporting duties.
  • Research offices and sponsors: NICE and NHS adoption are separate steps from MHRA authorisation, as the Pinsent Masons commentary stresses. Budget for health technology assessment evidence alongside regulatory evidence.

What happens next

The MHRA has not published a date for the Early Access service in the documents above; its July 2025 statement said further information on innovation pathways would be available soon. The IDAP guidance page remains the record of the pilot, and its update history is the place to check for further changes to the remaining pilot participants. For other recent MHRA developments, see our report on the MHRA AdvanceGxP medicines manufacturing service.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →